NSPR InspireMD, Inc.

NSPR financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1433607 Exchange: Nasdaq SIC: 3841 (Surgical & Medical Instruments & Apparatus)
Showing 3 of 17 annual and 0 of 59 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$60.93M (Jun 2025)
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(888) 776-6804
EIN
262123838
Headquarters
MIAMI, FL, 33126
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Saguaro Resources, Inc. (2009–2011)

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
$10.84M
Net Income
$-52.48M
Total Assets
$44.64M
Total Equity
$31.51M
Total Debt
-
Free Cash Flow
$-42.46M
Ratios
Gross Margin
18.1%
Operating Margin
-494%
Net Margin
-484.1%
Return on Equity
-166.6%
Return on Assets
-117.6%
Current Ratio
3.8x
FCF / Assets
-95.1%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

InspireMD, Inc. generated $8.98M of revenue in fiscal 2025, with net loss of $48.79M and an operating cash outflow of $35.10M. At $8.98M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Revenue was 28.1% above fiscal 2024 revenue of $7.01M, marking a year-over-year increase. The company reported diluted EPS of -$0.76, adding a shareholder-level measure to the absolute income figures considered below. The company employed $69.40M of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 0.13x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

After reported cost of revenue, the company retained $2.65M as gross profit before recognizing operating expenses and other items. Gross margin was 29.5%, so that share of each revenue unit remained after the cost of revenue reported for the period. The company recorded an operating loss of $49.61M after the reported operating expense base. Relative to revenue, the operating deficit measured 552.6%, showing the shortfall after operating costs. The company ended the period with a net loss of $48.79M, extending the operating result through all remaining items. The net loss equaled 543.3% of revenue, showing the bottom-line deficit relative to the company’s sales base. EBITDA was $426.39M, adding a pre-interest, tax, depreciation, and amortization view of the company’s earnings capacity. The pretax result was a loss of $48.72M, establishing the deficit before tax effects. The pretax loss equaled 542.6% of revenue, measuring the pre-tax deficit against sales. The reported income-tax provision was $63.00K, the amount recognized between pretax income and the final net-income result. The net loss equaled 88.4% of period-end equity, showing the deficit relative to book capital. Relative to total assets, the net loss represented 70.3%. Compared with a $32.01M net loss in fiscal 2024, the current loss increased to $48.79M.

Liquidity and Capital Structure

The company held $69.40M of assets against $14.20M of liabilities and $55.20M of equity, revealing how the asset base was financed. The near-term balance sheet paired $61.47M of current assets with $10.71M of current liabilities at the reporting date. Current assets covered current liabilities by 5.74x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $8.94M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 83.4% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was 79.5%, placing book capital against the total resource base. Relative to total assets, liabilities measured 20.5%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 12.9%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 48.3% from $46.81M in fiscal 2024, leaving current total assets higher year over year. Against $36.09M of equity in fiscal 2024, the current book-equity balance moved 53.0% and ended higher. The reported cash balance changed 52.7% from $18.92M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $35.10M, rather than cash generation from operations. Capital expenditures used $1.66M in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Negative free cash flow was $36.77M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to revenue, the post-investment cash deficit represented 409.5%. The free-cash-flow deficit equaled 53.0% of total assets, placing the cash shortfall against the company’s resource base.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual (FY)
Quarterly 🔒
Chart 🔒
Annual financial statements for InspireMD, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $8.98M $7.01M $6.21M
Cost of Revenue $6.33M $5.50M $4.40M
Gross Profit $2.65M $1.51M $1.81M
OPERATING EXPENSES
R&D Expense $15.00M $13.63M $7.98M
SG&A Expense $20.71M $15.31M $11.10M
Other Operating Expenses (derived) $16.55M $6.07M $3.87M
Operating Income $-49.61M $-33.50M $-21.14M
NON-OPERATING INCOME / EXPENSE
Other Income/Expense $891.00K $1.56M $1.29M
Pretax Income $-48.72M $-31.95M $-19.85M
Income Tax $63.00K $59.00K $65.00K
Net Income $-48.79M $-32.01M $-19.92M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.76 $-0.76 $-0.82
Diluted Shares 64.33M 41.93M 24.27M
EBITDA $426.39M $246.50M $210.86M
Depreciation & Amortization $476.00M $280.00M $232.00M
Balance Sheet
ASSETS
Cash & Equivalents $8.94M $18.92M $9.64M
Short-term Investments $45.27M $15.72M $29.38M
Accounts Receivable $2.17M $1.57M $1.80M
Inventory $3.40M $2.57M $2.11M
Other Current Assets $1.30M $1.06M $578.00K
Current Assets $61.47M $40.52M $44.16M
PP&E (Net) $3.58M $2.37M $1.06M
Noncurrent Assets $7.93M $6.29M $3.48M
Total Assets $69.40M $46.81M $47.64M
LIABILITIES
Other Current Liabilities $336.00K $255.00K $190.00K
Current Liabilities $10.71M $7.68M $6.02M
Noncurrent Liabilities $3.49M $3.04M $2.12M
Total Liabilities $14.20M $10.72M $8.14M
EQUITY
Common Stock $4.00K $3.00K $2.00K
Additional Paid-in Capital $357.49M $289.59M $261.00M
Retained Earnings $-302.29M $-253.51M $-221.50M
Total Equity $55.20M $36.09M $39.50M
Total Liabilities & Equity $69.40M $46.81M $47.64M
SUPPLEMENTAL
Shares Outstanding 43.53M 26.61M 21.84M
Check: A − (L + E + NCI) - - -
Cash Flow Statement
Cash from Operations $-35.10M $-21.87M $-16.38M
Capital Expenditures $1.66M $1.40M $381.00K
Cash from Investing $-30.56M $12.64M $-16.09M
Cash from Financing $55.57M $18.45M $37.53M
Free Cash Flow $-36.77M $-23.27M $-16.76M
Beginning Cash (CFS) $18.92M $9.64M -
Net Change in Cash $-10.09M $9.23M -
Effect of FX on Cash $117.00K $51.00K $-58.00K
Calculated Ending Cash $8.94M $18.92M -
Cash per BS $8.94M $18.92M $9.64M
Cash scope difference (CFS − BS) - - -
Cash per CFS $8.94M $18.92M $9.64M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is InspireMD, Inc.'s annual revenue?

InspireMD, Inc. reported $10.84M in revenue for trailing twelve months (ending June 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is InspireMD, Inc. profitable?

No. InspireMD, Inc. reported $-52.48M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does InspireMD, Inc. generate free cash flow?

No. Free cash flow was $-42.46M for trailing twelve months. Operating cash flow was $-41.21M.